Alamar Biosciences appointed Robert Ragusa to its Board of Directors as a Class I Director effective September 1, 2026, with his term expiring at the 2027 Annual Meeting. He was simultaneously assigned to the Audit, Compensation, and Nominating and Corporate Governance Committees. Compensation follows the existing Non-Employee Director Policy, and standard indemnification agreements were executed. Alamar Biosciences operates in the biotechnology industry, focusing on the development of targeted therapies for cancer.

Alamar Biosciences reported second quarter 2026 financial results with total revenue of $29.4 million, an 82% increase from the prior year period. Consumable revenue surged 147% to $15.5 million, while instrument revenue grew 35% to $7.8 million and services revenue increased 49% to $6.2 million. The company reported a net loss of $13.2 million compared to $7.0 million in the prior year period, with operating expenses rising 89% to $31.2 million due to investments in headcount and R&D. Gross margin improved to 60% from 53%. Alamar provided full-year 2026 revenue guidance of $116 million to $120 million. The company maintains a cash position of $256.3 million as of June 30, 2026. Alamar Biosciences operates in the biotechnology and diagnostics industry, specializing in precision proteomics for disease detection.

Alamar Biosciences, Inc. announced the death of board member Ian Ratcliffe, who served as an independent director since February 2024. Following this event, the Board decreased its authorized number of directors to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee. Alamar Biosciences, Inc. is a biotechnology company that develops proteomic-based diagnostic solutions.